Celgene Corp (CELG)

CELG (NASDAQ:Drugs)
$108.20
pos +0.00
+0.00%
Today's Range: 107.89 - 109.21 | CELG Avg Daily Volume: 4,931,900
Last Update: 11/21/14 - 3:59 PM EST
Volume: 0
YTD Performance: 28.07%
Open: $0.00
Previous Close: $107.35
52 Week Range: $66.85 - $109.25
Oustanding Shares: 798,704,188
Market Cap: 85,740,894,582
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 16 16 16 16
Moderate Buy 1 1 1 1
Hold 2 2 3 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.26 1.26 1.35 1.43
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 56.20
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
56.20 56.20 25.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
18.04% 36.43% 252.90%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.90 0.79 0.21
Net Income -0.40 0.65 0.18
EPS 2.00 0.84 0.22
Earnings for CELG:
EBITDA 2.35B
Revenue 6.49B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.87 $n.a. $3.26 $4.50
Number of Analysts 3 0 2 3
High Estimate $0.88 $n.a. $3.26 $4.94
Low Estimate $0.85 $n.a. $3.26 $4.27
Prior Year $0.67 $0.73 $2.68 $3.26
Growth Rate (Year over Year) 30.83% n.a.% 21.64% 38.14%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Don't get too excited bidding CMI and CAT.
In this market, negativity is rarely being rewarded.
Investors are seeing growth today in three areas.
Beat the short-term crown in these three areas for the long term.

The Fibocall: Celgene Real Money Pro($)

This beloved stock has triggered a long-term overbought signal again.
Still, it's a good time to review what's happening, so we never forget.
The Fed event can actually be good for many stocks.
The next step is to know how much risk you can bear.

Aiming a Shotgun at Biotech Real Money Pro($)

I invest in biotech in a different way than any other sector.

Celgene Price Bump Real Money Pro($)

From The Street of Dreams

Columnist Conversations

Well this is confusing...our models were calling for a run to 2072 before a bearish reversal would be possible...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.